Q-omics provides the consensus-scored ZDHHC13 profile across patient tissues and cancer cell-line models. ZDHHC13 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ZDHHC13 is differentially expressed in 11, with the highest sampling consensus in BRCA. Additionally, ZDHHC13 RNA expression shows 20,469 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, BRCA, and ACC as cancer lineages where ZDHHC13 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZDHHC13 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZDHHC13 survival associations across molecular data types. ZDHHC13 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZDHHC13 RNA expression–survival associations across cancer types. High ZDHHC13 expression shows unfavorable associations in ACC, LGG, MESO and KIRP, but favorable associations in KIRC and COAD. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify KIRC as the clearest survival context for ZDHHC13 RNA expression.
This table summarizes ZDHHC13 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in BRCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ZDHHC13. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZDHHC13 shows lower tumor expression in THCA and higher tumor expression in BRCA, LUSC, LUAD, CHOL and STAD. The BRCA box plot shows higher ZDHHC13 RNA expression in tumor versus normal tissue (log2 FC = +0.952, t-test p < 0.001).
This table shows molecular features associated with ZDHHC13 in patient tissues and cancer cell lines. In patient samples, ZDHHC13 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZDHHC13 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Leukemia.
